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The International AIDS Society convened the 3rd International HIV/Viral Hepatitis Co-Infection Meeting on 17 July
2016 as part of the pre-conference program preceding the 21st International AIDS Conference held in Durban,
South Africa. The meeting brought together a diversity of scientific, technical and community interests to discuss
opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living
with HIV, particularly in low- and middle-income settings.
The objectives of the meeting were:
i. To review the latest therapeutic developments in viral hepatitis;
ii. To identify challenges such as high cost of medications for hepatitis C virus (HCV) and risk of developing viral
resistance, and successes, such as the provision of HCV treatment in community-based settings, movements to
reduce drug costs and increasing access, in relation to scaling up diagnosis, screening, antiviral treatment and
prevention of viral hepatitis;
iii. To advance the agenda for elimination of viral hepatitis as a public health problem.
Discussions centred around the six key interventions outlined by the World Health Organization Global Health Sector
Strategy on Viral Hepatitis 2016–2021: hepatitis B virus (HBV) vaccination (including birth dose); safe injection practices
plus safe blood; harm reduction among people who inject drugs; safer sex practices; hepatitis B treatment; and
hepatitis C cure.
This article summarizes the main issues and findings discussed during the pre-conference meeting. One of
the recommendations from the meeting delegates is universal implementation of birth dose vaccination for
HBV without further delay to prevent mother-to-child transmission of infection. There is also the need to
implement screening and treatment of hepatitis among pregnant women. A call was made for concerted
efforts to be put together by all stakeholders towards addressing some of the structural barriers, including
criminalization of drug use, discrimination and stigma that people living with viral hepatitis face. Finally, the
need for greater advocacy was highlighted to enable access to therapy of viral hepatitis at lower cost than
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currently prevails. Implementation of these resolutions will help in achieving the target of eliminating viral
hepatitis as a public health threat.
Keywords: HIV/viral hepatitis co-infection, Hepatitis B, Hepatitis C, Epidemiology, Prevention, Access and
equity of treatment, 21st International AIDS ConferenceIntroduction
The 3rd International HIV/Viral Hepatitis Co-Infection
Meeting (http://www.iasociety.org/co-infections/hepatitis),
chaired by Wendy Spearman, Marina Klein (in absentia)
and Jürgen Rockstroh, convened some 400 participants
from a variety of backgrounds, including researchers, epi-
demiologists, clinicians, funders, biomedical industry rep-
resentatives, policy makers, health activists and people
living with viral hepatitis and/or HIV.
The meeting was organized around six major themes:
i. Hepatitis B virus (HBV) topics
ii. Challenges in HBV management in resource-limited
settings
iii. Hepatitis C virus (HCV) epidemiology: The knowns
and the unknowns
iv. HCV treatment update: A moving target
v. New tools, new technologies
vi. Panel discussion - Accessing antivirals: Overcoming
remaining challenges.
Speakers delivered oral presentations, and selected au-
thors presented posters on issues that included: HBV epi-
demiology and outcomes; HCV epidemiology and natural
history; HCV testing, monitoring and management, and
HCV treatment access. This report presents the key points
of the meeting and concludes with the main outcomes
and the recommendations made by delegates.Background
Global estimates suggest that 240 million people were
living with chronic hepatitis B as of 2005 [1], while
80 million (95% confidence interval: 64–103) have
chronic HCV viraemia [2]. Despite the high numbers
of infected people, less than 5% of people living with
chronic viral hepatitis are aware that they are infected
because of the insidious nature of viral hepatitis in-
fections and lack of access to affordable diagnostics
[3]. Furthermore, according to statistics from the
2013 Global Burden of Disease Study, an estimated
1.45 million (95% uncertainty interval: 1.38–1.54)
people die each year from viral hepatitis-related dis-
eases, with 96% of these being due to HBV and HCV
infections [4]. The number of people who die from
viral hepatitis is greater than those who die from
HIV, tuberculosis or malaria; yet viral hepatitis (alsoincluding hepatitis A, D and E) does not get as much
attention [4]. Six to 10 million people are newly in-
fected with viral hepatitis annually, and this is despite
the existence of effective preventative measures and
therapeutic treatments, such as HBV vaccine and
antivirals, and direct acting antivirals (DAAs) for cure
of HCV [3].
There is an urgent need to strengthen equitable access to
prevention, screening, diagnosis and treatment services to
the most affected regions, particularly in low- and middle-
income settings, such as sub-Saharan Africa and Central
and East Asia. In May 2016, the World Health Assembly
adopted the Global Health Sector Strategy on Viral Hepa-
titis 2016–2021, whose objectives are aligned with those of
the Sustainable Development Goals. The strategy’s long-
term vision is to eliminate viral hepatitis as a public health
threat by 2030 through the reduction of new viral hepatitis
infections by 90% and the reduction of deaths related to
viral hepatitis by 65% from the 2015 figures [3].
It is in this context that the 3rd International HIV/Viral
Hepatitis Co-Infection Meeting opened with coverage of
the epidemiology and burden of disease related to HIV,
HBV and HCV infections. Despite viral hepatitis being
one of the 10 leading causes of mortality and morbidity
worldwide, there is an acute lack of global awareness
about the severity of the problem and a lack of commit-
ment to combat and eliminate the disease.
The burden and consequences of viral hepatitis are
not evenly distributed worldwide: Oceania, sub-Saharan
Africa and Asia have the highest viral hepatitis-related
mortality rates [4]. Moreover, it is well recognized that
co-infection with HIV and viral hepatitis is associated
with worse outcomes than being infected with HBV or
HCV alone, particularly with advanced immunodefi-
ciency [5, 6]. Patients co-infected with HIV and viral
hepatitis show rapid progression to cirrhosis and early
presentation with hepatocellular carcinoma (HCC)
compared with those infected with viral hepatitis alone
[7, 8]. Improved availability and access to appropriate
diagnosis and treatment is needed to reduce the number
of people with viral hepatitis-related liver diseases. The
elimination of viral hepatitis will require strong partner-
ships between affected communities, professional and
community organizations, national departments of
health, researchers, health care providers and the bio-
medical industry.
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HIV/HBV co-infection remains a global public health
challenge. In HBV endemic countries, childhood-acquired
hepatitis B infections usually precede HIV acquisition in
adulthood. Sub-Saharan Africa faces the dual challenge of
having both the highest prevalence of HIV infection and
also high endemicity of hepatitis B [1, 9]. The dual burden
of HBV and HIV infection poses a challenge in that
mortality from liver disease due to HIV/HBV co-infection
has been shown to be higher than due to HIV/HCV co-
infection, as shown by data from the Multicenter AIDS
Cohort Study where the liver-related mortality among
HIV-infected men with chronic hepatitis B was 13.4 per
1000 person-years compared with 7.2 per 1000 person-
years in those with hepatitis C [10].
HBV seroprevalence and transmission risks vary geo-
graphically. In low prevalence countries, hepatitis B is
usually acquired in adulthood either sexually or paren-
terally, e.g., from needle stick-injuries. In contrast, in HBV
endemic countries, mother-to-child transmission (MTCT)
and early childhood infection from infected older siblings
and playmates are the main routes of acquisition and are
responsible for the chronicity of infection. Up to 90% of ne-
onates born to HBV e antigen positive or highly viraemic
mothers (with HBV DNA >200,000 IU/ml) and 20–50%
with childhood infection (<5 years of age) will develop
chronic hepatitis B compared to <5% of those who acquire
hepatitis B as adults (>20 years of age). Thus, in HBV
endemic countries, interrupting early transmission is key to
breaking the cycle of ongoing HBV infection.
Prevention of MTCT of HBV and early childhood
acquisition significantly reduces the number of new in-
fections and eventually leads to the elimination of hepa-
titis B amongst neonates who serve as the reservoir of
infections and have a propensity for establishing chron-
icity. This can be achieved through a combination of
third trimester antiviral prophylaxis, hepatitis B hyper-
immune globulin (HBIG), hepatitis B birth dose (HepB-
BD) vaccination and ensuring full HBV vaccine coverage
as well as safe delivery practices.
The combined administration of HBIG and HepB-BD
monovalent vaccine within 24 h of delivery prevents
HBV MTCT in 80–95% cases [11, 12]. In resource-rich
settings, giving HBIG to infants born to pregnant
women with high HBV viral loads, in addition to the
HepB-BD vaccine, is standard of care to prevent HBV
MTCT. However, HBIG is expensive and is not readily
available in most HBV endemic countries and thus initi-
ation of prophylactic nucleoside analogue antiviral ther-
apy such as tenofovir in the third trimester should be
considered to further reduce the risk of MTCT. How-
ever, emphasis must be placed on the administration of
the HepB-BD monovalent vaccine within 24 h ofdelivery followed by the full HBV vaccine schedule (ei-
ther as two or three additional monovalent vaccines or
as a multivalent vaccine given according to the routine
Expanded Programme of Immunisation schedule). How-
ever, in 2014, only 96 of 194 WHO countries (49%) re-
ported offering HepB-BD vaccine as part of their
national immunization programmes and <38% of babies
born worldwide received the HepB-BD vaccine within
24 h after birth; and the WHO/UNICEF 2015 report es-
timated that only 80% infants received full vaccine
coverage [13, 14].
The impact of the rollout of the multivalent vaccines
has hampered the availability of the HBV monovalent
vaccine that is needed if countries are to implement the
WHO’s 2009 recommendation for a HepB-BD vaccine.
The fact that multivalent vaccines improve timeliness
and coverage rate of vaccination is not in doubt as these
are more acceptable because of the reduced number of
injections [15–17]. However, these improvements have
not entirely helped eliminate perinatal transmission of
hepatitis B in at-risk children who are not getting the
much-needed birth dose. Perhaps other countries could
learn from countries such as Colombia, where a HBV
monovalent birth dose is administered in addition to the
three doses of the multivalent vaccine [18]. There is little
to non-existent evaluation of a serological response fol-
lowing most vaccines in children. However, post-vaccine
serological testing (hepatitis B surface antigen, HBsAg,
and anti-HBs antibody) of HBV-exposed infants at 9–12
months (or 1 or 2 months after their last HBV vaccine,
if the vaccine series is delayed) as recommended in the
United States by the Center for Disease Control and Pre-
vention (CDC), enables confirmation of a serological re-
sponse (anti-HBs levels >10 mIU/mL) to the vaccine and
identification of infected infants [19]. Infants who are
HBsAg negative with anti-HBs levels <10 mIU/mL re-
quire repeat vaccination and those who have become
HBsAg positive need to be linked to care. However,
there are concerns regarding feasibility and cost of post-
vaccine serological testing in resource-limited settings.
All women who are pregnant should undergo ante-
natal screening for HBsAg, but this is currently not be-
ing done in many countries. This should be performed
at the same time as screening for HIV. Screening for
HBsAg could be achieved by rapid, point-of-care testing
as a way of identifying women who are infected with
HBV and need to receive appropriate intervention to
prevent MTCT of HBV as well as linkage to ongoing
care post-delivery. Identification of HBsAg positive
pregnant women provides further opportunities to
screen, vaccinate and identify potentially infected part-
ners, siblings and children thereby identifying clusters of
HBV infection and breaking cycles of HBV infection
within families. Unfortunately, there are currently
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Paediatric clinical trials are necessary to evaluate newer
drugs, such as tenofovir alafenamide, that are less
nephrotoxic and do not have as adverse an impact on
bone mineralization.
The inclusion of HBV screening into the routine ante-
natal testing schedule in highly endemic areas is important,
but this requires the prioritization of HBV mono-infection,
as there is a tendency to only be concerned about hepatitis
B in the context of HIV. This is exemplified by the fact that
the increasing availability of fixed-dose combinations (teno-
fovir, lamivudine/emtricitabine and efavirenz) for HIV ther-
apy has become a limiting factor for access to anti-HBV
therapeutic options, such as tenofovir that are needed by
HBV-mono-infected patients. As a result, governments in
resource-limited settings have to pay more in order to have
the same drugs that are subsidized for HIV when treating
hepatitis B. It appears that for the HBV-mono-infected
patients, being HIV negative is ironically “a disadvantage”
as it excludes many patients from accessing effective treat-
ment at a reasonable cost [20]. For example, the current
situation leads to only HIV/HBV-co-infected women bene-
fitting from HIV treatment programs because of dually
active antiretroviral therapy regimens that are effective
against HIV and HBV, while HBV-mono-infected pregnant
women are neglected and left at risk of transmitting infec-
tion to their babies. Routine screening and vaccination of
at-risk individuals is also important as is the treatment of
HBV infected individuals with active disease, but many
HBV-mono-infected individuals fail to access antiviral ther-
apy (tenofovir). Although the tools to effectively implement
elimination strategies exist, they remain unequally distrib-
uted and are not easily accessible where they are needed
most, particularly in resource-limited settings.
Despite progress made in terms of development of treat-
ment and vaccination programs for viral hepatitis, the
emergence of antiviral resistance mutations poses a threat,
especially from patients with high viral loads. These muta-
tions could be missed by diagnostic tests, cause reactiva-
tion of previous controlled HBV infections and could also
result in vaccine escape, thereby permitting infection [21].
The transmission of resistant HBV viruses has been re-
ported in several cases and could have an impact on the
subsequent efficacy of HBV therapeutic regimens [22, 23].
Fortunately, the public health impact of these immune es-
cape mutations appears to be limited for now, but more
research is needed to improve the detection of drug-
induced resistance and the related treatment failure. There
is also a need for surveillance efforts to detect the emer-
gence of these mutations.
There is also a need to update the current understanding
of the natural history of HBV and the associated disease
phases. The current understanding, especially of the
immune tolerant phase, seems outdated and negativelyimpacts on patient care [24, 25]. This is because data shows
that some perinatally infected children exhibit significant
liver disease despite being classified as being in the immune
tolerant phase, which is normally associated with minimal
liver disease [26, 27]. There is also evidence of clonal re-
population of hepatocytes in the immune tolerant phase in
some patients, suggestive of ongoing immune activity that
results in killing of infected hepatocytes. There is thus a
need for strengthened data collection in high-prevalence
areas to improve our understanding of the natural history
of hepatitis B.
In terms of HBV-related liver diseases, there is a need
for routine surveillance for HCC and other liver-related
complications of chronic hepatitis B infection. HCC was
the second most common cause of cancer mortality
worldwide, according to the 2012 GLOBOCAN data,
but its management is currently poor [28]. There is an
increase in the number of deaths linked to liver diseases,
including HCC, and a noted increased incidence of HCC
in people living with HIV who have HBV and/or HCV
co-infection [8, 29]. Therefore, there is a need to refine
the surveillance intervals in individuals with HIV co-
infection because HCC in these patients tends to be
more aggressive and grows more rapidly compared with
those with HBV mono-infection. Current HCC surveil-
lance recommendations are that there should be 6–12-
month screening intervals using ultrasound [30, 31]. For
example, the European Association for Study of the
Liver (EASL) Guidelines for HCC screening in HIV and
HCV/HBV co-infected individuals are similar to HCV
and HBV mono-infected patients with established cir-
rhosis i.e., 6 monthly ultrasounds and alpha-fetoprotein
levels [32]. In Africa, where access to ultrasound is lim-
ited, there may still be a role for alpha-fetoprotein in
HCC surveillance. As the risk of HCC is increased in
HIV and HBV/HCV co-infected individuals, is more
aggressive and occurs at a younger age, there has been
some discussion about shortening the length of screen-
ing intervals [33]. However, this may prove to be a
challenge, especially when the current surveillance rec-
ommendations for HCC are not standardized nor
systematically implemented in many countries. On a
health system level, there is a challenge in the short to
medium term to define delivery strategies for these
screening and surveillance programs.
Finally, there are unmet challenges in hepatitis B ther-
apy, such as the development of a cure. The discovery of
the attachment receptor for HBV and the RNA-guided
clustered regulatory interspaced short palindromic repeats
(CRISPR) and CRISPR associated (Cas) protein endonu-
cleases has led to the development of therapeutics aimed
at achieving cure of infected patients [34]. Some thera-
peutic efforts for hepatitis B cure are geared towards
elimination of HBV’s covalent closed circular DNA
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Hepatitis C topics: epidemiology, diagnostics and
treatment
An estimated 110 million people have antibodies to HCV,
which are considered serological evidence of current or past
infection with hepatitis C [2]. Central and East Asia regions
have high prevalence of HCV of above 3.5% in the general
population, while sub-Saharan Africa is considered to have
a moderate prevalence of between 1.5 and 3.5% [2].
People who inject drugs (PWID) are frequently mar-
ginalized by society and where coverage of needle and
syringe programmes and opioid substitution therapy are
limited, are at high risk of acquiring HIV and HCV
infection [36]. PWID, particularly in resource-limited
settings, are often unable to access testing and treatment
services where they exist because of structural barriers,
including the criminalization of drug use (i.e., policing),
discrimination and stigma [37, 38]. While there are gaps
in HCV epidemiology in Africa and other affected re-
gions, populations of PWID do exist and are often
underestimated, especially in eastern sub-Saharan Africa
[39]. Limited data regarding HCV and HIV infections
(and co-infections) among PWID is an obstacle to
improving access and provision of quality treatment.
There are very few African countries with harm reduc-
tion programs that include needle and syringe programs
and/or opioid substitution therapy. Where harm reduc-
tion services exist, the programs are implemented by
non-governmental organizations, which might indicate
the lack of prioritization of services for PWID by
governments of resource-limited countries [40]. These
programs could play a positive role in increasing access
to viral hepatitis-related services and, at the same time,
help in reducing new HIV infections [41].Fig. 1 a shows countries covered under voluntary licensing agreements from G
status of Sovaldi® (Gilead Sciences) and Daklinza® (Bristol-Meyers Squib) worldw
burden of hepatitis C is very high, while these drugs remain unregistered in subOther challenges include the absence of comprehensive
country-specific public health policies for prevention, diag-
nosis and treatment of viral hepatitis, the restricted registra-
tion and high prices of DAAs rendering these effective
drugs unavailable and unaffordable where they are needed,
and the expensive and centralized diagnostic platforms that
cannot be used in remote settings. Decentralized diagnostic
platforms using economical and quality-assured rapid tests
(serologic and RNA based) are important in facilitating
linkage to care and treatment. By increasing the turnaround
time for results, fewer patients would be lost to follow up
[42]. The effectiveness of decentralized testing has been
shown in HIV testing and treatment programs around the
world. More point-of-care and near point-of-care diagnos-
tic tools are being developed and becoming available, HCV
programmes should ensure prompt and at-scale implemen-
tation, as well as effective linkage to care.
Given the availability of newly developed curative ther-
apies, the elimination of HCV has become a real and
achievable goal. This will, however, necessitate a strategic
multifaceted approach. More specifically, the following
will be required: increased testing; high-quality harm re-
duction services; improved quality of formal and infor-
mal health services; increased access to affordable
treatment; development of a vaccine; and combatting
stigma and discrimination against people living with
hepatitis C. The role of resistance and resistance testing
for managing hepatitis C in light of the availability of
DAAs for treating hepatitis C must be carefully consid-
ered when feasible. Failure to achieve a sustained
virological response using interferon-free DAAs usually
involves HCV variants resistant to one or more DAAs.
However, the addition of ribavirin or extending treatment
duration increases the frequency with which a sustained
virologic response is achieved [43]. Most of the anti-
hepatitis C drug research and development has beenilead Sciences and Bristol-Meyers Squib, while 1B shows the registration
ide. The voluntary licensing agreements exclude some countries where the
-Saharan African countries and parts of Asia. (Source: http://mapcrowd.org)
Table 1 List of speakers and titles of presentationa
1. Andersson, Monique, Stellenbosch University & University Hospitals
NHS Trust, University of Oxford
‘PMTCT for HBV’
2. Andrieux-Meyer, Isabelle, MSF
Opening overview and community perspective’
3. Boyd, Anders, INSERM
‘HBV resistance and escape mutants’
4. Easterbrook, Philippa, WHO
‘WHO Diagnostic Guidelines’
5. Hardie, Diana, University of Cape Town
‘Screening for viral hepatitis: Diagnostics (HBV and HCV)’
6. Hellard, Margaret, Burnet Institute
‘Current trends worldwide: Implications for elimination’
7. Kennedy, Patrick, Barts and The London School of Medicine
‘Curing HBV: How close are we?’
‘HCC screening and management’
8. Khwairakpam, Giten, TREAT Asia
Panel discussion - ‘Accessing antivirals: Overcoming remaining
challenges’
9. Klein, Marina, McGill University; CIHR Canadian HIV Trials
Network (CTN)
‘Is a pan-genotypic therapy ready for prime time?’ (presented by
Rockstroh, Jürgen)
‘Closing remarks’ (presented by Rockstroh, Jürgen)
10. Luhmann, Niklas, Médecins du Monde
‘HCV in PWID in Africa: A hidden epidemic’
11. Medeiros, Nelson, OUT Wellbeing
Panel discussion - ‘Accessing antivirals: Overcoming remaining
challenges’
12. Meyers, Tammy, Chinese University of Hong Kong
‘Children and adolescents’
13. Perry, Greg, Medicines Patent Pool
‘Medicines Patent Pool’
14. Rajkumar, Nalinikanta, Community Network for Empowerment
(CoNE)
Panel discussion - ‘Accessing antivirals: Overcoming remaining
challenges’
15. Rockstroh, Jürgen, University of Bonn
‘Role of resistance and resistance testing for managing HCV’
16. Scheibe, Andrew, University of Cape Town & TB/HIV Care
Association
Panel discussion - ‘Accessing antivirals: Overcoming remaining
challenges’
17. Solomon, Sunil, Johns Hopkins University
‘Financing and scale up of HCV treatments: Entry of generics’
18. Sonderup, Mark, University of Cape Town
‘HBV-HIV co-infection: Epidemiology, vaccine and treatment coverage’
Panel discussion - ‘Accessing antivirals: Overcoming remaining
challenges’
19. Spearman, Wendy, University of Cape Town
‘Welcome and introduction’
‘Screening for viral hepatitis: Liver disease’
aSlide sets presented at the meeting are publicly available on the AIDS 2016
Online Conference Programme at http://programme.aids2016.org/Programme/
Session/1157 and on the IAS website
at http://www.iasociety.org/HIV-programmes/Co-Infections/3rd-International-HIV-
Viral-Hepatitis-Co-Infection-Meeting/Hepatitis-Meeting-Presentations
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numbers of HCV genotype 1 infection are found in
high-income countries [2, 44]. Unmet needs remain for
genotype 3 in particular. Pangenotypic therapies would
facilitate treatment, particularly in resource-limited
settings, as these could be used without costly pre-
treatment genotype assessment.
Although scaling up of treatment of hepatitis C is a
positive step, this alone is insufficient as awareness of
the infection is insufficient, especially among popula-
tions at high risk, such as PWID [45]. Treatment
programs must ensure that there is enough education of
patients, in addition to access to opioid substitution
therapy and harm reduction programs and services, to
avoid re-infections. In order to increase knowledge of
hepatitis C, we need to develop and implement
high-profile awareness and advocacy campaigns on viral
hepatitis, as well as prevention campaigns and harm re-
duction programs, as has been done for HIV.
With the introduction of generic DAAs, a cure is a
reality for people living with hepatitis C. However, the
price of originator HCV drugs is high and beyond the
reach of many patients, including those within resource-
rich settings [46]. Drug originators and the Medicines
Patent Pool should ensure that their voluntary licenses
not only cover as many low- and middle-income
countries as possible (currently, these exclude several
high-prevalence middle-income countries), but also that
the drugs get registered in the countries covered by
these licenses (see Fig. 1). When originators do not
register their medicines, they should facilitate registra-
tion by providing the relevant clinical trials data to
licensed generics manufacturers. Quality assurance
should also be considered a priority. Currently, only
Bristol-Myers Squibb has received WHO prequalifica-
tion for daclatasvir under the WHO Prequalification of
Medicines Programme. This is despite the fact that
daclatasvir production is sub-licensed to seven generic
manufacturers through the Medicines Patent Pool, and
that most of the anti-hepatitis C drugs are on the WHO
Model List of Essential Medicines.
New tools and new technologies
Viral hepatitis-related diagnosis and treatment services
do exist, but access to these is a considerable challenge.
There is a need for innovative models that could
improve diagnosis and treatment in resource-limited set-
tings. Such models include public-private partnerships
to unlock funding, and point-of-care diagnostic testing
that could be used in remote settings, enabling linkage
to care and treatment and also reducing loss to follow
up of infected patients. In designing new technologies
for diagnosis, it is worth considering the potential of
technologies such as loop mediated amplification testing
Table 2 Organizing committee - 3rd International HIV/Viral Hepatitis Co-Infection Meeting
Name Organization City, Country Role
Marina Klein McGill University
CIHR Canadian HIV Trials Network (CTN)
Montréal, Canada Co-chair
Wendy Spearman University of Cape Town Cape Town, South Africa Co-chair
Monique Andersson Stellenbosch University
Faculty of Health Sciences
Stellenbosch, South Africa Convener of HBV prevention and
management theme
Isabelle Andrieux-Meyer MSF Geneva, Switzerland Co-convener of HCV and HBV access
theme
Anchalee Avihingsanon HIV-NAT Bangkok, Thailand Co-convener of epidemiology and
disease burden theme
Sanjay Bhagani Royal Free Hospital London, UK Co-convener of complex issues in
HCV and HBV theme
Christoph Boesecke University of Bonn Bonn, Germany EACS Liaison
Laurent Castera Hôpital Beaujon Paris, France EASL Liaison
Curtis Cooper CIHR Canadian HIV Trials Network (CTN) Ottawa, Canada Co-convener of HCV therapeutic
development theme
Greg Dore Kirby Institute, University of New South Wales Sydney, Australia Convener of treatment in special
populations theme
Jordan Feld University of Toronto Toronto, Canada Convener of HBV therapeutic
development theme
Karine Lacombe Hôpital Saint-Antoine Paris, France Convener of epidemiology and disease
burden theme
Gail Matthews Kirby Institute, University of New South Wales Sydney, Australia Convener of complex issues in
HCV and HBV theme
Sébastien Morin International AIDS Society Geneva, Switzerland Point contact for coordination with the
IAS and AIDS 2016
Marion Peters University of California San Francisco, USA Co-convener of HBV therapeutic development
theme
Jürgen Rockstroh University of Bonn Bonn, Germany Convener of treatment in special
populations theme
Mark Sulkowski Viral Hepatitis Center, Johns Hopkins Division
of Infectious Diseases
Baltimore, USA Convener of HCV therapeutic
development theme
Tracy Swan MSF Access Campaign New York, USA Convener of HCV and HBV access theme
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ple equipment, with results being read using the naked
eye [47]. Again, these would be useful in remote settings
where there is no specialized equipment similar to that
seen in centralized laboratories.
Furthermore, non-invasive tests for screening of liver
diseases are required when initiating and monitoring re-
sponse to therapy and also for monitoring of disease
progression in patients with viral hepatitis [48]. There
are two general classes of non-invasive tests, namely
serum-based tests and radiological tests, as well as a
combination of both. The WHO Diagnostic Guidelines,
drafted in the context of the WHO Global Health Sector
Strategy on Viral Hepatitis 2016–2021 [3, 42], emphasize
the fact that testing for viral hepatitis is crucial because
it is at the core of the care, treatment and prevention
cascade. The WHO Diagnostic Guidelines focus on
lower-income countries and adopt a public health ap-
proach, promoting standardized, simplified, cost-effective, equitable and feasible approaches to dealing
with the burden of undiagnosed and untreated viral
hepatitis infection.
Conclusions - overcoming remaining challenges
More reliable and detailed data on key populations and
access to diagnostic platforms, including point-of-care
tests and treatment, are needed, as is increased public
awareness. Accessible, affordable and caring health ser-
vices are necessary to strengthen screening, diagnosis,
treatment and prevention of viral hepatitis. Civil and
community activism can be re-energised as the tools
exist, but their effectiveness is hindered by a lack of
awareness and political commitment. On this point, les-
sons could be learned from the HIV response in terms
of access to affordable health services, awareness and
PMTCT. What is needed now is concrete and concerted
action from all stakeholders to eliminate viral hepatitis
as a public health threat.
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focus on resource-limited settings to deliver cost-
effective, simplified and standardized treatment and pre-
vention national programs and surveillance strategies.
The fact that hepatitis C can now be cured should
provide encouragement. However, several challenges
remain, including the need for more WHO prequalified
HCV drugs, the need for originators to ensure access to
their drugs by registering (or at least facilitate registra-
tion) in all countries, and the need for improving access
to treatment for people with HBV mono-infection.
In conclusion, delegates of the 3rd International HIV/
Viral Hepatitis Co-Infection Meeting agreed on the
following advocacy priorities:
i. Universal implementation of birth dose vaccination
for hepatitis B without further delay
ii. Sustainable access to antiviral therapy for HBV
mono-infected individuals
iii. Increased diagnosis and treatment of viral hepatitis,
particularly HCV among PWID
iv. End of stigmatization of people living with HIV
and/or viral hepatitis.
Abbreviations
DAAs: Direct acting antivirals; HBV: Hepatitis B virus; HCC: Hepatocellular
carcinoma; HCV: Hepatitis C virus; MTCT: Mother-to-child transmission;
PMTCT: Prevention of mother-to-child transmission; PWID: People who inject
drugs; WHO: World Health Organization
Acknowledgements
This article draws on the IAS rapporteur summary presented at the 2016
International AIDS Conference by TM and RMM (available here: http://
programme.aids2016.org/Programme/Session/1157). The authors would like to
acknowledge the 3rd International HIV/Viral Hepatitis Co-Infection Meeting
presenters and organizing committee members (see Tables 1 and 2,
respectively). Most meeting presentations are available for download on the
AIDS 2016 and IAS websites.
Funding
The meeting was funded through grants from AbbVie, ContraVir Pharmaceuticals,
European AIDS Clinical Society (EACS), Gilead Sciences, and MSD, and with other
support from the CIHR Canadian HIV Trials Network (CTN) and European
Association for the Study of the Liver (EASL). Funders did not have a role in the
writing of this paper. MBK is supported by a Chercheur National career award
from the Fonds de recherche Québec - Santé (FRQ-S).
Availability of data and materials
Not applicable.
Authors’ contributions
RMM and TM drafted the first version of the text. All authors contributed to
subsequent versions, read and approved the final manuscript.
Competing interests
TM, RMM, AS, TS and IAM declare that they have no competing interests. SM
coordinates the work of the IAS Industry Liaison Forum, which is supported by
unrestricted grants from Abbott, AbbVie, Alere, Beckman Coulter, Cepheid, Cipla,
Female Health Company, Gilead Sciences, Janssen, MSD, Lupin Pharmaceuticals,
Omega Diagnostics, Roche Molecular Systems, Sysmex Corporation, and ViiV
Healthcare. CWS received honoraria as a speaker for Gilead Sciences. MBK
received research grants for investigator-initiated trials from Merck and ViiV
Healthcare; consulting fees from AbbVie, Bristol-Meyers Squibb, Gilead Sciences,
Merck,, and ViiV Healthcare,. JKR received honoraria for consulting or speaking ateducational events from Abbott, AbbVie, Bionor Pharma, Bristol-Meyers Squibb,
Cipla, Gilead Sciences, Hexal, Janssen, Merck and ViiV Healthcare.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Medical Virology, University of Stellenbosch, Faculty of Medicine
and Health Sciences, Stellenbosch, South Africa. 2Urban Futures Centre,
Durban University of Technology, Durban, South Africa. 3HIV Programmes
and Advocacy, International AIDS Society, Geneva, Switzerland. 4TB/HIV Care
Association and Desmond Tutu HIV Centre, Cape Town, South Africa.
5Treatment Action Group, New York, USA. 6Médecins Sans Frontières, Access
Campaign, Geneva, Switzerland. 7Division of Hepatology, Department of
Medicine, University of Cape Town, Cape Town, South Africa. 8Chronic Viral
Illness Service, McGill University Health Centre, Montreal, Canada.
9Department of Medicine I, University Hospital Bonn, Bonn, Germany.
Received: 20 November 2016 Accepted: 29 March 2017
References
1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis
B virus infection: new estimates of age-specific HBsAg seroprevalence and
endemicity. Vaccine. 2012;30:2212–9.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology
and genotype distribution of the hepatitis C virus infection. J Hepatol.
2014;61:S45–57.
3. WHO. Global health sector strategy on viral hepatitis, 2016–2021. 2016.
4. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I,
et al. The global burden of viral hepatitis from 1990 to 2013: findings from
the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.
5. Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on
survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11:521–6.
6. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, et al.
Immunosuppression may lead to progression of hepatitis C virus-associated
liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol.
1996;91:2563–8.
7. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and
outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-
Canadian multicenter study. J Hepatol. 2007;47:527–37.
8. Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M,
Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in
HIV-infected patients in Spain. Clin Infect Dis. 2013;56:143–50.
9. UNAIDS. UNAIDS FACT SHEET 2015. 2015. p. 8.
10. Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative
risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C
virus infection. Clin Infect Dis. 2012;55:507–13.
11. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with
failure to passive-active immunoprophylaxis in infants born to HBsAg-
positive mothers. J Viral Hepat. 2012;19:e18–25.
12. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation
in newborn infants of mothers positive for hepatitis B surface antigen:
systematic review and meta-analysis. BMJ. 2006;332:328–36.
13. World Health Organisaion W. WHO/UNICEF coverage estimates 2014
revision. 2015.
14. Casey RM, Dumolard L, Danovaro-Holliday MC, Gacic-Dobo M, Diallo MS,
Hampton LM, et al. Global Routine Vaccination Coverage, 2015. MMWR
Morb Mortal Wkly Rep. 2016;65:1270–3.
15. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of
combination vaccines has improved timeliness of vaccination in children.
Pediatr Infect Dis J. 2006;25:507–12.
Maponga et al. Hepatology, Medicine and Policy  (2017) 2:8 Page 9 of 916. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M,
et al. Use of combination vaccines is associated with improved coverage
rates. Pediatr Infect Dis J. 2007;26:496–500.
17. Decker MD. Principles of pediatric combination vaccines and practical issues
related to use in clinical practice. Pediatr Infect Dis J. 2001;20:S10–8.
18. Choconta-Piraquive LA, De la Hoz-Restrepo F, Sarmiento-Limas CA.
Compliance with birth dose of Hepatitis B vaccine in high endemic and
hard to reach areas in the Colombian amazon: results from a vaccination
survey. BMC Health Serv Res. 2016;16:293.
19. Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW. Update: Shortened Interval
for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected
Mothers. MMWR Morb Mortal Wkly Rep. 2015;64:1118–20.
20. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited
countries and access to antiviral therapies: current and future challenges.
Future Virol. 2013;8:371–80.
21. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential
impact of immune escape mutations G145R and P120T on the replication
of lamivudine-resistant hepatitis B virus e antigen-positive and -negative
strains. J Virol. 2010;84:1026–33.
22. Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, et al. Prevalence
and clinical characterization of patients with acute hepatitis B induced by
lamivudine-resistant strains. J Gastroenterol Hepatol. 2010;25:745–9.
23. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a
lamivudine-resistant hepatitis B virus. AIDS. 2002;16:131–3.
24. Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV
infection: new perspectives on an old concept. Cell Mol Immunol.
2015;12:258–63.
25. Gill US, Kennedy PT. New insights in the management of chronic hepatitis
B. Clin Med (Lond). 2015;15:191–6.
26. Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of
asymptomatic HBsAg carrier children infected in the perinatal period:
clinical and liver histologic studies. Hepatology. 1988;8:374–7.
27. Hsu HC, Lin YH, Chang MH, Su IJ, Chen DS. Pathology of chronic hepatitis B
virus infection in children: with special reference to the intrahepatic
expression of hepatitis B virus antigens. Hepatology. 1988;8:378–82.
28. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
29. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al.
Hepatocellular carcinoma in HIV-infected patients: epidemiological features,
clinical presentation and outcome. AIDS. 2004;18:2285–93.
30. Bruix J, Sherman M, American Association for the Study of Liver D.
Management of hepatocellular carcinoma: an update. Hepatology.
2011;53:1020–2.
31. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom
and how? Therap Adv Gastroenterol. 2011;4:5–10.
32. EASL-EORTC. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
33. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral
control on the incidence of hepatocellular carcinoma in veterans with
hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr.
2015;68:456–62.
34. Maepa MB, Roelofse I, Ely A, Arbuthnot P. Progress and Prospects of Anti-
HBV Gene Therapy Development. Int J Mol Sci. 2015;16:17589–610.
35. Zoulim F. Are novel combination therapies needed for chronic hepatitis B?
Antiviral Res. 2012;96:256–9.
36. UNAIDS. DO NO HARM: HEALTH, HUMAN RIGHTS AND PEOPLE WHO USE
DRUGS. 2016. p. 144.
37. Bowring AL, Luhmann N, Pont S, Debaulieu C, Derozier S, Asouab F, et al.
An urgent need to scale-up injecting drug harm reduction services in
Tanzania: prevalence of blood-borne viruses among drug users in Temeke
District, Dar-es-Salaam, 2011. Int J Drug Policy. 2013;24:78–81.
38. Lepretre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, et al.
Prevalence and behavioural risks for HIV and HCV infections in a population
of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS
Soc. 2015;18:19888.
39. Crime UNOoDa. World Drug Report. 2016.
40. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al.
HIV prevention, treatment, and care services for people who inject drugs: a
systematic review of global, regional, and national coverage. Lancet.
2010;375:1014–28.41. Kermode M, Crofts N, Kumar MS, Dorabjee J. Opioid substitution therapy in
resource-poor settings. Bull World Health Organ. 2011;89:243.
42. Easterbrook PJ, Group WHOGD. Who to test and how to test for chronic
hepatitis C infection -. WHO testing guidance for low- and middle-income
countries. J Hepatol. 2016;2016(65):S46–66.
43. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM,
et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B,
or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Gastroenterology. 2016;151:501–12. e501.
44. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am
J Gastroenterol. 2014;109:628–35. quiz 636.
45. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker
O, et al. Burden of hepatitis C virus disease and access to hepatitis C virus
services in people who inject drugs in India: a cross-sectional study. Lancet
Infect Dis. 2015;15:36–45.
46. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al.
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30
Countries: An Economic Analysis. PLoS Med. 2016;13:e1002032.
47. St John A, Price CP. Existing and Emerging Technologies for Point-of-Care
Testing. Clin Biochem Rev. 2014;35:155–67.
48. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am
J Gastroenterol. 2004;99:1160–74.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
